WEST PHARMACEUTICAL SERVICES INC Q1 FY2025 earnings call

Eric Green began by discussing Q1 performance, noting solid revenues and adjusted EPS driven by GLP-1s and reduced industry-wide destocking. Proprietary products business had 0.6% revenue growth (2.1% organic), with HVP components growth affected by mix and timing but GLP-1 elastomer business at 7% of total revenues. AnnexOne revenues were 200 basis points of total revenues, stronger than expected. Contract Manufacturing segment saw revenue growth in GLP-1 auto injector offsetting CGM contract exits. Bernard Birkett discussed financial results, organic sales growth, adjusted operating profit, gross profit margin, and adjusted diluted EPS. Mentioned drivers of organic sales, margin performance, cash flow metrics. Announced executive leadership changes, with Shane Campbell joining as Senior Vice President of Chief Proprietary Segment Officer.

Proprietary Products: Organic net sales increased 2.4% in Q1. High-value products (73% of proprietary product sales) grew low single digits. Biologics market unit had mid-single digit organic net sales growth. Pharma market unit grew mid-single digits, while generics market unit declined mid-single digits. Contract Manufacturing segment had low single digit net sales growth in Q1, primarily driven by an increase in sales of self-injection devices for obesity and diabetes.

Increased full-year 2025 revenue guidance to $2.945 billion to $2.975 billion from prior $2.875 billion to $2.905 billion. Organic sales growth expected 2%-3%, unchanged. Adjusted diluted EPS guidance raised to $6.15 to $6.35 from $6 to $6.20. Second quarter revenue expected $720 million to $730 million, adjusted diluted EPS $1.05 to $1.55. 2025 CapEx guidance $275 million, unchanged.

Tariffs: Net impact of $20 million to $25 million for remaining quarters of 2025, with uncertainty due to retaliatory tariffs and other factors. Operational challenges: Constraints in one facility affecting HVP components supply, and pricing lower than expected in some areas.

Q: At what percent utilization are you assuming in the new site in Dublin?

A: Utilization is quite low as ramping up earlier this year, incorporated into guidance.

Q: Margin seems better on adjusted op margin in 1Q. Is it business mix or improved at delivery devices?

A: Better efficiencies in E and PC business, improvement in contract manufacturing margin, lighter spend in SG&A and R&D.

Q: On the guidance and the Hausaio product mid-single digit growth. Is that purely a function of timing and inventory destocking?

A: Factors include pricing lower than anticipated and a constraint in one facility affecting supply, but expect step up in HVP components in second half.

Q: Thoughts on government spending impact on demand?

A: Not seeing patterns change, demand visible increase, consistent with prior quarter.

Q: Utilization in Dublin site and demand spillover into 2026?

A: Demand constraint in one HPP plant, initiatives to address, potential spillover into 2026.

Q: Tariffs impact on components and finished goods, tax offset?

A: Tariffs in components and sourcing, various mitigations, future tax benefits possible but materialize later.

Q: Price contribution in quarter and forward-looking price?

A: Quarter had good price contribution, forward-looking price lighter than originally estimated.

Q: Management team rebuilding and leadership for growth?

A: Natural evolution of leadership, bringing new leaders, excited about new additions like Shane Campbell.

Q: AnnexOne potential upside and customer anecdotes?

A: Excited about AnnexOne, growing projects, mix shift effect, long-term growth, more in pharma/generic than biologics.

Q: Contract manufacturing transition and SmartDose margins?

A: Positioned well with contract manufacturing, SmartDose has two-pronged approach, focus on automation to improve margins.

Q: SmartDose pricing discussions and tariff surcharge in guidance?

A: No pricing in guidance, tariffs a moving target with mitigation efforts.

Q: Operating margin guidance and path to 23% LRP?

A: Not guiding operating margin, need to get back to LRP with biologics growth, AnnexOne, and mix shift.

Q: Year progress and restructuring costs?

A: Year progressing as anticipated, restructuring costs not reoccurring, savings embedded in guidance.

Q: Order trends in high-value components?

A: Destocking consistent, orders support second half ramp, favorable view on order patterns.

Q: Automated line timeline and GLP growth beyond GLPs?

A: Automated line on schedule, confident in timeline, excited about broader business growth with new drug launches.